-
Discussing the discrepancy between analytical calculations and the observed biological effectiveness in proton boron capture therapy (pbct)
Authors:
G. A. P. Cirrone,
G. Petringa,
A. Attili,
D. Chiappara,
L. Manti,
V. Bravatà,
D. Margarone,
M. Mazzocco,
G. Cuttone
Abstract:
A work recently published experimentally demonstrates an increase in the radiobiological efficacy of clinical proton beams when a tumour is treated in the presence of a concentration of 11B. The paper, for the first time, demonstrates the potential role of the p+11B to 3α (for brevity, p-B) reaction in the biological enhancement of proton therapy effectiveness. The work reports robust experimental…
▽ More
A work recently published experimentally demonstrates an increase in the radiobiological efficacy of clinical proton beams when a tumour is treated in the presence of a concentration of 11B. The paper, for the first time, demonstrates the potential role of the p+11B to 3α (for brevity, p-B) reaction in the biological enhancement of proton therapy effectiveness. The work reports robust experimental data in terms of clonogenic cell survival and chromosomal aberrations and unambiguously shows the presence of an enhancement when cells were exposed to a clinical proton beam subject to treatment with sodium boroncaptate (BSH). Moreover, the greater occurrence of complex-type chromosomal exchanges points to the effect as due radiation of a LET (Linear Energy Transfer) greater than that of protons alone, possibly the alpha particles generated by the reaction. At the same time, we emphasized that analytical calculations, performed on the basis of the well-known total production cross section data, are not able to explain the effect in a macroscopic way, i.e. solely in terms of a trivial increase in the total dose released in the cells by the alpha-particles. In this paper, thanks to simulations and analytical calculations, we will discuss the theoretically expected alpha particle yield and the corresponding LET and RBE (Relative Biological Effectiveness) increase related to the 11B presence. We conclude that a mere calculation based on the classical concepts of integral Dose, and average LET and RBE cannot be used to justify the observed radiobiological phenomena. We, therefore, suggest that micro- and nano-dosimetric aspects must be taken into account.
△ Less
Submitted 14 October, 2018;
originally announced October 2018.
-
Response to the authors of 'On the (un)effectiveness of Proton Boron Capture in Proton Therapy'
Authors:
GAP Cirrone,
G Cuttone,
L Manti,
D. Margarone,
G Petringa,
L. Giuffrida,
A. Minopoli,
A. Picciotto,
G. Russo,
F. Cammarata,
P. Pisciotta,
F. M. Perozziello,
F. Romano,
V. Marchese,
G. Milluzzo,
V. Scuderi,
G. Cuttone,
G. Korn
Abstract:
This manuscript provides a response to a recent report by Mazzone et al. available online on arXiv that, in turn, tentatively aims at demonstrating the inefficacy of proton boron capture in hadrotherapy. We clarify that Mazzone et al. do not add any scientific or technical insights to the points extensively discussed in the original manuscript by Cirrone et al., and/or in the series of iterations…
▽ More
This manuscript provides a response to a recent report by Mazzone et al. available online on arXiv that, in turn, tentatively aims at demonstrating the inefficacy of proton boron capture in hadrotherapy. We clarify that Mazzone et al. do not add any scientific or technical insights to the points extensively discussed in the original manuscript by Cirrone et al., and/or in the series of iterations had with the Referee, which ultimately lead to the publication of our original and pioneering experimental work. Here we summarize some of the key points of the long scientific debate we had during the review process of paper by Cirrone et al., which are very similar to the considerations presented by Mazzone et al.. In conclusion, no quantitative explanation of our robust experimental achievements presented in Cirrone et al. is provided in Mazzone et al.
△ Less
Submitted 9 March, 2018;
originally announced March 2018.
-
Nuclear fusion enhances cancer cell killing efficacy in a protontherapy model
Authors:
GAP Cirrone,
L Manti,
D Margarone,
L Giuffrida,
A. Picciotto,
G. Cuttone,
G. Korn,
V. Marchese,
G. Milluzzo,
G. Petringa,
F. Perozziello,
F. Romano,
V. Scuderi
Abstract:
Protontherapy is hadrontherapy fastest-growing modality and a pillar in the battle against cancer. Hadrontherapy superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET (Linear Energy Transfer) $^{12}$C ions can overcome cancer radioresistance: DNA lesion complexity incr…
▽ More
Protontherapy is hadrontherapy fastest-growing modality and a pillar in the battle against cancer. Hadrontherapy superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET (Linear Energy Transfer) $^{12}$C ions can overcome cancer radioresistance: DNA lesion complexity increases with LET, resulting in efficient cell killing, i.e. higher Relative Biological Effectiveness (RBE). However, economic and radiobiological issues hamper $^{12}$C-ion clinical amenability. Thus, enhancing proton RBE is desirable. To this end, we exploited the p + $^{11}$B $\rightarrow$3$α$ reaction to generate high-LET alpha particles with a clinical proton beam. To maximize the reaction rate, we used sodium borocaptate (BSH) with natural boron content. Boron-Neutron Capture Therapy (BNCT) uses $^{10}$B-enriched BSH for neutron irradiation-triggered alpha-particles. We recorded significantly increased cellular lethality and chromosome aberration complexity. A strategy combining protontherapy ballistic precision with the higher RBE promised by BNCT and $^{12}$C-ion therapy is thus demonstrated.
△ Less
Submitted 25 January, 2017;
originally announced January 2017.
